(Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced positive results from the clinical study of its AI-powered HYLA ...

Inspira Technologies* reports groundbreaking clinical results for its AI-powered HYLA blood sensor, achieving 96% accuracy in a key parameter and 92.3% accuracy in detecting oxygen deficiencies.

(IINN), Tuesday announced that the company has announced positive results from the clinical study of its AI-powered HYLA blood sensor, which is designed to monitor blood parameters. During the ...